Sanofi's Innovative Drug Cablivi® Approved in China for Immune-Mediated Thrombotic Thrombocytopenic Purpura

On November 5, Sanofi's innovative drug Cablivi was approved for marketing by the National Medical Products Administration (NMPA) in China. It is indicated for use in combination with plasma exchange and immunosuppressive therapy to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adult patients and adolescents aged 12 years and above with a body weight of at least 40 kg. Coinciding with the first day of the China International Import Expo (CIIE), Sanofi also showcased this drug at the event. Wang Shi, President of Sanofi Greater China, stated: "Thanks to the national support for the expedited review of urgently needed rare disease treatments, Cablivi has entered the ‘fast track’ for evaluation in China, taking only six months from submission to approval." (Yicai)

(This article is from Yicai)